Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)
China · Delayed Price · Currency is CNY 37.63
+0.08 (0.21%)
Sep 14, 2026, 3:00 PM CST
SHA:688050 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,279 | 11,732 | 17,254 | 18,107 | 24,264 | 22,103 | |
Market Cap Growth | -52.54% | -32.01% | -4.71% | -25.37% | 9.78% | 21.53% |
Enterprise Value | 8,037 | 11,882 | 17,625 | 17,747 | 24,232 | 21,769 |
Last Close Price | 37.63 | 60.17 | 89.83 | 94.00 | 125.77 | 114.41 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.66 | 43.75 | 44.42 | 59.57 | 104.27 | 129.00 |
Forward PE | 19.84 | 26.56 | 29.85 | 46.16 | 81.03 | 105.28 |
PS Ratio | 4.47 | 7.91 | 12.24 | 19.04 | 41.87 | 51.04 |
PB Ratio | 2.31 | 3.95 | 6.55 | 7.69 | 12.64 | 12.70 |
P/TBV Ratio | 3.73 | 4.88 | 8.30 | 9.93 | 14.01 | 14.16 |
P/FCF Ratio | 34.23 | 47.69 | 944.35 | - | - | - |
P/OCF Ratio | 21.71 | 31.78 | 49.62 | 85.16 | 97.01 | 100.79 |
PEG Ratio | - | 1.31 | 1.31 | 1.31 | 1.94 | 2.52 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.93 | 8.01 | 12.50 | 18.66 | 41.82 | 50.27 |
EV/EBITDA Ratio | 15.66 | 22.66 | 31.14 | 46.64 | 89.28 | 115.75 |
EV/EBIT Ratio | 23.83 | 32.56 | 40.29 | 57.59 | 104.62 | 137.88 |
EV/FCF Ratio | 37.80 | 48.30 | 964.66 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.39 | 0.20 | 0.23 | 0.18 | 0.09 | 0.09 |
Debt / EBITDA Ratio | 2.39 | 1.13 | 1.07 | 1.09 | 0.59 | 0.82 |
Debt / FCF Ratio | 5.76 | 2.44 | 33.33 | - | - | - |
Net Debt / Equity Ratio | 0.16 | -0.07 | 0.04 | -0.06 | -0.35 | -0.46 |
Net Debt / EBITDA Ratio | 0.99 | -0.37 | 0.20 | -0.36 | -2.48 | -4.25 |
Net Debt / FCF Ratio | 2.34 | -0.79 | 6.17 | 0.87 | 32.25 | 8.69 |
Asset Turnover | 0.38 | 0.40 | 0.43 | 0.36 | 0.27 | 0.24 |
Inventory Turnover | 1.80 | 1.90 | 2.11 | 1.77 | 1.31 | 1.18 |
Quick Ratio | 2.38 | 3.01 | 2.86 | 2.05 | 6.39 | 7.37 |
Current Ratio | 3.24 | 3.94 | 3.95 | 2.71 | 7.19 | 8.02 |
Return on Equity (ROE) | 6.99% | 8.59% | 15.51% | 13.38% | 12.42% | 10.21% |
Return on Assets (ROA) | 4.85% | 6.18% | 8.34% | 7.26% | 6.75% | 5.35% |
Return on Invested Capital (ROIC) | 7.65% | 10.99% | 15.82% | 15.53% | 18.22% | 18.78% |
Return on Capital Employed (ROCE) | 8.10% | 10.50% | 13.70% | 11.50% | 11.00% | 8.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.26% | 2.29% | 2.25% | 1.68% | 0.96% | 0.78% |
FCF Yield | 2.92% | 2.10% | 0.11% | -0.87% | -0.09% | -0.42% |
Dividend Yield | 0.81% | 0.53% | 0.39% | 0.29% | 0.22% | 0.18% |
Payout Ratio | 65.33% | 33.36% | 18.17% | 20.19% | 19.10% | 17.81% |
Buyback Yield / Dilution | -1.75% | -1.10% | 0.27% | -0.25% | -0.17% | -17.57% |
Total Shareholder Return | -0.94% | -0.57% | 0.66% | 0.04% | 0.06% | -17.39% |